SCHEMBL30239555

SCHEMBL30239555

CCOC(=O)c1cn(CCNC(=O)OC(C)(C)C)nc1C1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
MAPT P10636 1/20 0.37
FOS P01100 1/20 0.37
JUN P05412 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
DHODH Q02127 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24931213 0.87 JAK2 (0.42) JAK2JAK1ALDH1A1HPGDKDM4E
SCHEMBL31518572 0.83 ADORA3 (0.43) ALDH1A1HPGDKDM4EADORA3ADORA2A
SCHEMBL18764872 0.81 ADORA3 (0.40) ALDH1A1HPGDKDM4EADORA3ADORA2A
SCHEMBL31518447 0.78 ADORA3 (0.39) ALDH1A1HPGDKDM4EADORA3ADORA2A
SCHEMBL30239158 0.78 MAPK1 (0.47) JAK2ALDH1A1HPGDADORA3ADORA2A
SCHEMBL24931118 0.77 CRHBP (0.45) ALDH1A1ADORA3ADORA2ATSHRMAPT
SCHEMBL31518542 0.77 ADORA2A (0.42) KDM4EADORA3ADORA2AMEN1KMT2A
SCHEMBL15884484 0.75 ELANE (0.43) ALDH1A1HPGDKDM4EADORA3ADORA2A
SCHEMBL29333846 0.75 MGLL (0.44) ALDH1A1HPGDKDM4EADORA3ADORA2A
SCHEMBL25169810 0.75 FAAH (0.39) JAK2JAK1ALDH1A1KDM4EADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 CN disclosed
EP-4373816-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) Dana-Farber Cancer Institute, Inc. (US) 2024-05-29 EP disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 JAK2 3264/4885JAK1 2510/4885ALDH1A1 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.